USPTO serial 78881284
2036
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BAKER, JORDAN A
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with 2036?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Clarke Holman
JOHN CLARKE HOLMAN JACOBSON HOLMAN PLLC400 7TH ST NWWASHINGTON, DC 20004-2237UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, veterinary, and sanitary preparations, all used for the treatment of infectious diseases, namely, respiratory infections, eye infections, for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders, for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases, for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases, for the treatment of the musculo-skeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, for use in ophthalmology, for the treatment of dental and oral diseases, for use in gastroenterology; for the treatment of the respiratory system, for use in ocular disorders, for the treatment of cardiovascular diseases, acne medication, allergy medication, antacids, anthelmintics, anti-arrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medications, calcium channels blockers, central nervous system depressants, central nervous system stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives; dietetic substances, namely foods, adapted for medical use; vitamin supplements, mineral food supplements; herbal extracts for medical purposes; medicated extracts of plants and herbs in the form of capsules, tablets, liquid concentrate, powder, and crystals; dietetic supplements for medical use and nutritious health food supplement for medical use all made primarily of lingzhi spores, lingzhi spore lipids, yunzhi, bee glue or propolis, or cordyceps or extracts therefrom; lingzhi granules, lingzhi pills, lingzhi capsules, lingzhi tablets; and medicinal tea made primarily of lingzhi spores; Chinese herbal medicines, and Chinese patent medicines all composed of lingzhi spores, lingzhi spore lipids, yunzhi, bee glue, propolis, or cordyceps, and used for the treatment of infectious diseases, namely, respiratory infections, eye infections, for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders, for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases, for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases, for the treatment of the musculo-skeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, for use in ophthalmology, for the treatment of dental and oral diseases, for use in gastroenterology, for the treatment of the respiratory system, for use in ocular disorders, for the treatment of cardiovascular diseases, acne medication, allergy medication, antacids, anthelmintics, anti-arrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medications, calcium channels blockers, central nervous system depressants, central nervous system, stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 25, 2008 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 25, 2008 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 23, 2007 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 31, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 11, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| May 10, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 2, 2007 | ALIE | ASSIGNED TO LIE | — |
| Apr 12, 2007 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Apr 12, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 12, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 12, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 10, 2007 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 9, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 9, 2007 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 16, 2006 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 16, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 14, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 26, 2006 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jun 26, 2006 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| May 17, 2006 | NWAP | NEW APPLICATION ENTERED | — |